進行性家族性肝内胆汁うっ滞治療市場：薬剤タイプ、流通チャネル、エンドユーザー別-2025年～2030年の世界予測

進行性家族性肝内胆汁うっ滞治療市場は、2023年に1億1,352万米ドルと評価され、2024年には1億1,862万米ドルに達すると予測され、CAGR 4.65％で成長し、2030年には1億5,614万米ドルに達すると予測されています。

進行性家族性肝内胆汁うっ滞症（PFIC）は、胆汁の流れの障害（胆汁うっ滞）を特徴とするまれな遺伝性肝障害の一群を表し、肝障害につながる可能性があります。PFICの治療には、遺伝子治療や薬剤開発などの新規介入により、症状を管理し、肝機能を改善し、治癒の可能性のある効果的な治療法を開発することが含まれます。PFIC治療への取り組みの必要性は、重篤な肝障害を予防し、罹患患者の生活の質を改善する可能性によって強調されます。最終用途は主に病院、専門クリニック、研究機関です。

PFIC治療市場は、希少疾患に対する認識の高まり、遺伝子研究の進歩、ヘルスケア支出の増加といった成長要因の影響を受けています。企業が遺伝子治療や新規低分子薬のような革新的な治療オプションに注力する中で、新たな科学的発見や希少疾患研究を奨励する規制の枠組みによって可能性を秘めた治療機会が生まれつつあります。こうした機会を活用するために、利害関係者は共同研究のための学術機関との提携に投資し、希少疾病用医薬品開発のための政府のインセンティブを活用すべきです。

しかし、市場開拓は、研究開発コストの高さ、新興国市場における希少疾患の臨床試験の複雑さ、有病率の低さによる患者募集の課題といった限界に直面しています。また、少数の患者集団における有効性を実証するための厳しいガイドラインを考えると、規制当局の経路をうまく利用することも難しいです。

技術革新という点では、CRISPRのような遺伝子編集技術や、早期診断のためのバイオマーカー開発などが最適な分野です。さらに、AI主導のアナリティクスは、患者データの分析と試験の最適化に革命をもたらす可能性があります。PFIC治療市場は、本質的にニッチでありながら急速な成長の可能性を秘めています。イノベーションを促進し、アンメット・メディカル・ニーズに効果的に対処するためには、製薬企業、研究者、ヘルスケアプロバイダーの間で透明性を保ちながら協力関係を継続することが極めて重要です。

市場力学：急速に進化する進行性家族性肝内胆汁うっ滞治療市場の主要市場インサイトを公開

進行性家族性肝内胆汁うっ滞治療市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • ヘルスケアインフラの改善による進行性家族性肝内胆汁うっ滞の発見の増加
  • PFIC治療拡大のための患者支援団体の役割拡大
• 市場抑制要因
  • PFIC治療へのアクセスおよび治療費の問題
• 市場機会
  • PFICの調査と診断技術の進歩
  • PFIC治療に対する政府の好意的な承認
• 市場の課題
  • PFIC疾患管理と治療効果の複雑さ

ポーターの5つの力：進行性家族性肝内胆汁うっ滞治療市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：進行性家族性肝内胆汁うっ滞治療市場における外部からの影響の把握

外部マクロ環境要因は、進行性家族性肝内胆汁うっ滞治療市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析進行性家族性肝内胆汁うっ滞治療市場における競合情勢の把握

進行性家族性肝内胆汁うっ滞治療市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス進行性家族性肝内胆汁うっ滞治療市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、進行性家族性肝内胆汁うっ滞治療市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限はベンダーを明確かつ正確に区分し、ユーザーが戦略目標に最適なパートナーやソリューションを特定するのに役立ちます。

本レポートは、主要な注目分野を網羅した包括的な市場分析を提供しています：

1.市場の浸透度：業界主要企業の広範なデータを含む、現在の市場環境の詳細なレビュー。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • ヘルスケアインフラの改善により進行性家族性肝内胆汁うっ滞症の検出が増加
    • PFIC治療の拡大に向けた患者擁護団体の役割拡大
  • 抑制要因
    • PFIC治療へのアクセスと費用負担の問題
  • 機会
    • PFIC調査と診断技術の進歩
    • PFIC治療に対する政府の好意的な承認
  • 課題
    • PFIC疾患管理と治療効果の複雑さ
• 市場セグメンテーション分析
  • 薬剤の種類：肝臓と血液中の胆汁酸濃度を下げるためのコレスチラミンの使用増加
  • 流通チャネル：処方薬への継続的かつ便利なアクセスのためにオンライン薬局が好まれます。
  • エンドユーザー：PFICの重篤な合併症を管理するために病院でPFIC治療が行われる可能性は高い
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 進行性家族性肝内胆汁うっ滞治療市場：薬剤タイプ別

• コレスチラミン
• リファンピシン
• ウルソデオキシコール酸

第7章 進行性家族性肝内胆汁うっ滞治療市場：流通チャネル別

• 病院薬局
• オンライン薬局
• 小売薬局

第8章 進行性家族性肝内胆汁うっ滞治療市場：エンドユーザー別

• 外来手術センター
• 病院
• 専門クリニック

第9章 南北アメリカの進行性家族性肝内胆汁うっ滞治療市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋の進行性家族性肝内胆汁うっ滞治療市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの進行性家族性肝内胆汁うっ滞治療市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
  • FDAが進行性家族性肝内胆汁うっ滞症患者の掻痒管理にLivmarliを承認
  • カナダ政府は、進行性家族性肝内胆汁うっ滞症を含む希少疾患の子供たちの健康状態を改善するために2,000万カナダドルを割り当てます。
  • フランス政府、Vivet Therapeuticsの革新的な遺伝子治療開発に490万ユーロの助成金を授与
  • カナダ保健省がPFIC関連掻痒症に対するBylvay（オデビキシバット）を承認
  • CANbridge Pharmaceuticals、CAN108 NDAのNMPA承認を取得
  • UKRI、進行性家族性肝内胆汁うっ滞症およびその他の希少疾患の調査推進に1,400万ポンドを充当
  • ジェダイト・メディシンズ、日本で第3相試験と希少疾病用医薬品指定によりPFICの治療を前進させる
  • インドは希少疾患の治療を強化し、PFICと患者ケアの強化に重点を置いて40カロールインドルピーを割り当てた。
  • イプセン、アルビレオファーマの戦略的買収により希少疾患治療薬の提供を強化

企業一覧

• AbbVie, Inc.
• Calliditas Therapeutics AB
• CANbridge Pharmaceuticals Inc.
• Centurion Laboratories Private Limited
• CymaBay Therapeutics, Inc.
• Enomark
• Glenmark Pharmaceuticals Limited
• Healthy Life Pharma Pvt. Ltd.
• Hebei Xingang Pharmaceutical Co., Ltd.
• Intercept Pharmaceuticals, Inc.
• Ipsen Pharma
• Jackson Laboratories Pvt Ltd.
• Macleods Pharmaceuticals Ltd.
• Mirum Pharmaceuticals, Inc.
• Novartis AG
• Par Pharmaceuticals, Inc. by Endo International PLC
• Pfizer Inc.
• Sanofi S.A.
• SiNi Pharma Pvt. Ltd.
• Taj Pharmaceuticals Limited
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.
• Vivet Therapeutics
• Wellona Pharma
• Zoic Biotech Pvt. Ltd.

LIST OF FIGURES

• FIGURE 1. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET RESEARCH PROCESS
• FIGURE 2. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, 2018-2030 (USD THOUSAND)
• FIGURE 4. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD THOUSAND)
• FIGURE 5. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD THOUSAND)
• FIGURE 6. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD THOUSAND)
• FIGURE 8. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD THOUSAND)
• FIGURE 10. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD THOUSAND)
• FIGURE 12. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD THOUSAND)
• FIGURE 14. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD THOUSAND)
• FIGURE 16. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD THOUSAND)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD THOUSAND)
• FIGURE 20. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, 2018-2030 (USD THOUSAND)
• TABLE 4. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 5. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
• TABLE 6. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET DYNAMICS
• TABLE 7. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
• TABLE 8. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY CHOLESTYRAMINE, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 9. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY RIFAMPICIN, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 10. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY URSODEOXYCHOLIC ACID, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 11. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
• TABLE 12. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 13. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 14. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 15. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
• TABLE 16. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 17. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 18. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD THOUSAND)
• TABLE 19. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
• TABLE 20. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
• TABLE 21. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
• TABLE 22. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
• TABLE 23. ARGENTINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
• TABLE 24. ARGENTINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
• TABLE 25. ARGENTINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
• TABLE 26. BRAZIL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
• TABLE 27. BRAZIL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
• TABLE 28. BRAZIL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
• TABLE 29. CANADA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
• TABLE 30. CANADA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
• TABLE 31. CANADA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
• TABLE 32. MEXICO PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
• TABLE 33. MEXICO PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
• TABLE 34. MEXICO PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
• TABLE 35. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
• TABLE 36. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
• TABLE 37. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
• TABLE 38. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD THOUSAND)
• TABLE 39. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
• TABLE 40. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
• TABLE 41. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
• TABLE 42. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
• TABLE 43. AUSTRALIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
• TABLE 44. AUSTRALIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
• TABLE 45. AUSTRALIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
• TABLE 46. CHINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
• TABLE 47. CHINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
• TABLE 48. CHINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
• TABLE 49. INDIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
• TABLE 50. INDIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
• TABLE 51. INDIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
• TABLE 52. INDONESIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
• TABLE 53. INDONESIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
• TABLE 54. INDONESIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
• TABLE 55. JAPAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
• TABLE 56. JAPAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
• TABLE 57. JAPAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
• TABLE 58. MALAYSIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
• TABLE 59. MALAYSIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
• TABLE 60. MALAYSIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
• TABLE 61. PHILIPPINES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
• TABLE 62. PHILIPPINES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
• TABLE 63. PHILIPPINES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
• TABLE 64. SINGAPORE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
• TABLE 65. SINGAPORE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
• TABLE 66. SINGAPORE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
• TABLE 67. SOUTH KOREA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
• TABLE 68. SOUTH KOREA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
• TABLE 69. SOUTH KOREA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
• TABLE 70. TAIWAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
• TABLE 71. TAIWAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
• TABLE 72. TAIWAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
• TABLE 73. THAILAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
• TABLE 74. THAILAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
• TABLE 75. THAILAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
• TABLE 76. VIETNAM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
• TABLE 77. VIETNAM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
• TABLE 78. VIETNAM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
• TABLE 83. DENMARK PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
• TABLE 84. DENMARK PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
• TABLE 85. DENMARK PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
• TABLE 86. EGYPT PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
• TABLE 87. EGYPT PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
• TABLE 88. EGYPT PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
• TABLE 89. FINLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
• TABLE 90. FINLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
• TABLE 91. FINLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
• TABLE 92. FRANCE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
• TABLE 93. FRANCE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
• TABLE 94. FRANCE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
• TABLE 95. GERMANY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
• TABLE 96. GERMANY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
• TABLE 97. GERMANY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
• TABLE 98. ISRAEL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
• TABLE 99. ISRAEL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
• TABLE 100. ISRAEL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
• TABLE 101. ITALY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
• TABLE 102. ITALY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
• TABLE 103. ITALY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
• TABLE 104. NETHERLANDS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
• TABLE 105. NETHERLANDS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
• TABLE 106. NETHERLANDS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
• TABLE 107. NIGERIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
• TABLE 108. NIGERIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
• TABLE 109. NIGERIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
• TABLE 110. NORWAY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
• TABLE 111. NORWAY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
• TABLE 112. NORWAY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
• TABLE 113. POLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
• TABLE 114. POLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
• TABLE 115. POLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
• TABLE 116. QATAR PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
• TABLE 117. QATAR PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
• TABLE 118. QATAR PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
• TABLE 119. RUSSIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
• TABLE 120. RUSSIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
• TABLE 121. RUSSIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
• TABLE 122. SAUDI ARABIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
• TABLE 123. SAUDI ARABIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
• TABLE 124. SAUDI ARABIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
• TABLE 125. SOUTH AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
• TABLE 126. SOUTH AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
• TABLE 127. SOUTH AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
• TABLE 128. SPAIN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
• TABLE 129. SPAIN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
• TABLE 130. SPAIN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
• TABLE 131. SWEDEN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
• TABLE 132. SWEDEN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
• TABLE 133. SWEDEN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
• TABLE 134. SWITZERLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
• TABLE 135. SWITZERLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
• TABLE 136. SWITZERLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
• TABLE 137. TURKEY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
• TABLE 138. TURKEY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
• TABLE 139. TURKEY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
• TABLE 140. UNITED ARAB EMIRATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
• TABLE 141. UNITED ARAB EMIRATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
• TABLE 142. UNITED ARAB EMIRATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
• TABLE 143. UNITED KINGDOM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD THOUSAND)
• TABLE 144. UNITED KINGDOM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD THOUSAND)
• TABLE 145. UNITED KINGDOM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD THOUSAND)
• TABLE 146. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 147. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

The Progressive Familial Intrahepatic Cholestasis Treatment Market was valued at USD 113.52 million in 2023, expected to reach USD 118.62 million in 2024, and is projected to grow at a CAGR of 4.65%, to USD 156.14 million by 2030.

Progressive Familial Intrahepatic Cholestasis (PFIC) represents a group of rare genetic liver disorders characterized by impaired bile flow (cholestasis), which can lead to liver damage. The scope of PFIC treatment involves developing effective therapies to manage symptoms, improve liver function, and potentially cure the disease through novel interventions such as gene therapy and drug development. The necessity of addressing PFIC treatment is underscored by its potential to prevent severe liver damage and improve life quality for affected patients, often necessitating liver transplantation in severe cases. Applications span from pharmaceutical development to advanced diagnostic tools, while the end-use scope primarily includes hospitals, specialty clinics, and research institutions.

The PFIC treatment market is influenced by growth factors such as increasing awareness of rare diseases, advancements in genetic research, and a rise in healthcare expenditure. Opportunities are emerging as companies focus on innovative treatment options like gene therapies and novel small-molecule drugs, which hold potential due to new scientific discoveries and regulatory frameworks encouraging rare disease research. To capitalize on these opportunities, stakeholders should invest in partnerships with academic institutions for research collaborations and leverage government incentives for orphan drug development.

However, the market faces limitations such as high research and development costs, the complexity of clinical trials for rare diseases, and challenges in patient recruitment due to the disease's low prevalence. Navigating regulatory pathways can also be difficult, given the stringent guidelines for demonstrating efficacy in small patient populations.

In terms of innovation, the best areas to explore include gene editing technologies, such as CRISPR, and developing biomarkers for early diagnosis. Additionally, AI-driven analytics could revolutionize patient data analysis and trial optimization. The PFIC treatment market is inherently niche yet poised for rapid growth; ongoing transparency and collaboration among pharmaceutical companies, researchers, and healthcare providers are crucial for fostering innovation and addressing unmet medical needs effectively.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Progressive Familial Intrahepatic Cholestasis Treatment Market

The Progressive Familial Intrahepatic Cholestasis Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing detection of progressive familial intrahepatic cholestasis with improvements in healthcare infrastructure
  • Expanding role of patient advocacy groups to expand PFIC treatments
• Market Restraints
  • Access and affordability issues of PFIC treatments
• Market Opportunities
  • Advancements in PFIC research and diagnostic technologies
  • Favorable government approvals for PFIC treatments
• Market Challenges
  • Complexity in PFIC disease management and treatment efficacy

Porter's Five Forces: A Strategic Tool for Navigating the Progressive Familial Intrahepatic Cholestasis Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Progressive Familial Intrahepatic Cholestasis Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Progressive Familial Intrahepatic Cholestasis Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Progressive Familial Intrahepatic Cholestasis Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Progressive Familial Intrahepatic Cholestasis Treatment Market

A detailed market share analysis in the Progressive Familial Intrahepatic Cholestasis Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Progressive Familial Intrahepatic Cholestasis Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Progressive Familial Intrahepatic Cholestasis Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Progressive Familial Intrahepatic Cholestasis Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Inc., Calliditas Therapeutics AB, CANbridge Pharmaceuticals Inc., Centurion Laboratories Private Limited, CymaBay Therapeutics, Inc., Enomark, Glenmark Pharmaceuticals Limited, Healthy Life Pharma Pvt. Ltd., Hebei Xingang Pharmaceutical Co., Ltd., Intercept Pharmaceuticals, Inc., Ipsen Pharma, Jackson Laboratories Pvt Ltd., Macleods Pharmaceuticals Ltd., Mirum Pharmaceuticals, Inc., Novartis AG, Par Pharmaceuticals, Inc. by Endo International PLC, Pfizer Inc., Sanofi S.A., SiNi Pharma Pvt. Ltd., Taj Pharmaceuticals Limited, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Viatris Inc., Vivet Therapeutics, Wellona Pharma, and Zoic Biotech Pvt. Ltd..

Market Segmentation & Coverage

This research report categorizes the Progressive Familial Intrahepatic Cholestasis Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Type, market is studied across Cholestyramine, Rifampicin, and Ursodeoxycholic Acid.
• Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
• Based on End-Users, market is studied across Ambulatory Surgical Centers, Hospitals, and Specialty Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing detection of progressive familial intrahepatic cholestasis with improvements in healthcare infrastructure
    • 5.1.1.2. Expanding role of patient advocacy groups to expand PFIC treatments
  • 5.1.2. Restraints
    • 5.1.2.1. Access and affordability issues of PFIC treatments
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in PFIC research and diagnostic technologies
    • 5.1.3.2. Favorable government approvals for PFIC treatments
  • 5.1.4. Challenges
    • 5.1.4.1. Complexity in PFIC disease management and treatment efficacy
• 5.2. Market Segmentation Analysis
  • 5.2.1. Drug Type: Rising usage of cholestyramine for reducing the level of bile acids in the liver and blood
  • 5.2.2. Distribution Channel: Preference for online pharmacies for continuous and convenient access to prescribed medications.
  • 5.2.3. End-Users: High potential for PFIC treatments in hospitals to manage severe complications of PFIC
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Drug Type

• 6.1. Introduction
• 6.2. Cholestyramine
• 6.3. Rifampicin
• 6.4. Ursodeoxycholic Acid

7. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Distribution Channel

• 7.1. Introduction
• 7.2. Hospital Pharmacies
• 7.3. Online Pharmacies
• 7.4. Retail Pharmacies

8. Progressive Familial Intrahepatic Cholestasis Treatment Market, by End-Users

• 8.1. Introduction
• 8.2. Ambulatory Surgical Centers
• 8.3. Hospitals
• 8.4. Specialty Clinics

9. Americas Progressive Familial Intrahepatic Cholestasis Treatment Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Progressive Familial Intrahepatic Cholestasis Treatment Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Progressive Familial Intrahepatic Cholestasis Treatment Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. FDA Endorses Livmarli for Pruritus Management in Progressive Familial Intrahepatic Cholestasis Patients
  • 12.3.2. Canadian Government Allocates CAD 20 Million to Enhance Health Outcomes for Children with Rare Diseases, Including Progressive Familial Intrahepatic Cholestasis
  • 12.3.3. French Government Awards Euro 4.9 Million Grant for Innovative Gene Therapy Development by Vivet Therapeutics"
  • 12.3.4. Approval of Bylvay (odevixibat) by Health Canada for PFIC-Related Pruritus
  • 12.3.5. CANbridge Pharmaceuticals Gains NMPA Approval for CAN108 NDA
  • 12.3.6. UKRI Allocates GBP 14 Million to Advance Research on Progressive Familial Intrahepatic Cholestasis and Other Rare Diseases
  • 12.3.7. Jadeite Medicines Advances Treatment for PFIC with Phase 3 Trial and Orphan Drug Designation in Japan
  • 12.3.8. India Boosts Rare Diseases Treatment, Allocates INR 40 Crore with a Focus on PFIC and Enhanced Patient Care
  • 12.3.9. Ipsen Enhances Rare Disease Offerings with Strategic Acquisition of Albireo Pharma

Companies Mentioned

• 1. AbbVie, Inc.
• 2. Calliditas Therapeutics AB
• 3. CANbridge Pharmaceuticals Inc.
• 4. Centurion Laboratories Private Limited
• 5. CymaBay Therapeutics, Inc.
• 6. Enomark
• 7. Glenmark Pharmaceuticals Limited
• 8. Healthy Life Pharma Pvt. Ltd.
• 9. Hebei Xingang Pharmaceutical Co., Ltd.
• 10. Intercept Pharmaceuticals, Inc.
• 11. Ipsen Pharma
• 12. Jackson Laboratories Pvt Ltd.
• 13. Macleods Pharmaceuticals Ltd.
• 14. Mirum Pharmaceuticals, Inc.
• 15. Novartis AG
• 16. Par Pharmaceuticals, Inc. by Endo International PLC
• 17. Pfizer Inc.
• 18. Sanofi S.A.
• 19. SiNi Pharma Pvt. Ltd.
• 20. Taj Pharmaceuticals Limited
• 21. Takeda Pharmaceutical Company Limited
• 22. Teva Pharmaceutical Industries Ltd.
• 23. Viatris Inc.
• 24. Vivet Therapeutics
• 25. Wellona Pharma
• 26. Zoic Biotech Pvt. Ltd.